Navigation Links
Johnson & Johnson Announces Settlement With U.S. Department of Justice and U.S. Securities and Exchange Commission
Date:4/8/2011

NEW BRUNSWICK, N.J., April 8, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) announced today it will pay $70,006,316 in fines, disgorgement and interest, an amount previously reserved for, in a settlement related to publicly disclosed Foreign Corrupt Practices Act (FCPA) investigations by the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC). The Company hopes to reach a settlement of a related investigation by the U.K. Serious Fraud Office (SFO) in several days.  

In 2007, Johnson & Johnson voluntarily disclosed to the DOJ and the SEC that subsidiaries outside the United States were believed to have made improper payments in connection with the sale of medical devices.  In the course of comprehensive compliance efforts and reports into the Company, similar issues in additional markets and businesses were identified and brought to the attention of the agencies.

As part of the settlement, Johnson & Johnson has entered into a Deferred Prosecution Agreement (DPA) with the DOJ and a Consent to Final Judgment with the SEC. These agreements reflect the recognition by DOJ and SEC of Johnson & Johnson's voluntary disclosures and subsequent cooperation, as well as the company's compliance efforts over the past four years.  If the company completes three years of enhanced FCPA compliance undertakings and reporting to the DOJ and the SEC, the charges filed by the DOJ against a subsidiary company will be dismissed.  

"More than four years ago, we went to the government to report improper payments and have taken full responsibility for these actions," said William C. Weldon, Chairman and Chief Executive Officer.  "We are deeply disappointed by the unacceptable conduct that led to these violations.  We have undertaken significant changes since then to improve our compliance efforts, and we are committed to doing everything we can to ensure this does not occur again."

Today's settlement also resolves an investigation of Johnson & Johnson subsidiary companies in the United Nations Oil for Food Program, which was not disclosed by the Company to the DOJ and SEC.  A U.N.-commissioned report related to the Oil for Food Program alleged that more than 2,000 companies worldwide acquiesced to the Iraqi government's demands between 2001 and 2003 that they pay a ten percent fee as a condition of importing humanitarian goods into the country.  

Mr. Weldon added, "I know that these actions are not representative of Johnson & Johnson employees around the world who do what is honest and right every day, in the conduct of our business and in service to patients and customers worldwide.  We will continue to demonstrate that Johnson & Johnson is a company that embraces responsible corporate behavior."

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections.  Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Woman Files Suit in Beaumont, Texas Federal Court Against DePuy Orthopaedics and Johnson & Johnson Over Recalled Hip Device
2. Woman Files Suit in Federal Court Against DePuy Orthopaedics, Inc.,/Johnson & Johnson Over Recalled Hip Device
3. Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs
4. Johnson & Johnson to Participate in 2011 Citi Global Health Care Conference
5. Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional
6. Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
7. Johnson & Johnson Recall of DePuy Hip Devices: Lewitt Hackman Files Suit
8. Johnson & Johnson Receives Approval from European Commission
9. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
10. Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results
11. Johnson & Johnson Provides Update on McNeil Consumer Healthcare Remediation; Announces Completion of Internal Assessment Phase of Comprehensive Action Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017   Risperdal lawsuits involving gynecomastia (male ... with use of the atypical antipsychotic medication continue to ... Court of Common Pleas, where the state,s Risperdal docket ... to a notice posted on the Court,s website ... on March 9, 2017 at 11:00 a.m. (In Re: ...
(Date:2/17/2017)... Feb. 17, 2017  Featuring new ... at the  2017 HIMSS Conference & Exhibition (HIMSS17 ),  ... a global leader in health ... of population health management, acute healthcare ... integrated in a highly secure, cloud-based ...
(Date:2/17/2017)... 17, 2017  Noble Capital Markets announced today that ... (Nasdaq: EPIX ). The report was issued ... , PhD. ESSA Pharmaceuticals is a clinical ... cancer (CRPC). Its lead compound EPI-506, is a small ... of the androgen receptor, thereby has potential to overcome ...
Breaking Medicine Technology:
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... ... 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing facility ... Ken was impressed with the safety and reliability of the Stannah Stairlift as well ... This endorsement by Ken Matthews can be heard on News Radio WHP 580 ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette White, has ... Life Radio network. The episode, which was posted this week, features a 30-minute ... led to Park Cities Pet Sitter’s being awarded the 2017 National Association of Professional ...
(Date:2/18/2017)... ... February 18, 2017 , ... ... latest information and contact points to easily connect elderly veterans of America's armed ... and elder-care funding. It also conveys material on this year's increase in the ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... has not kept pace. Enovate Medical has introduced an innovative workstation designed to ... of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly mobile, ...
Breaking Medicine News(10 mins):